newsfilter
← Earnings
Earnings Releases·

Elutia — Third Quarter 2026 Earnings Summary

Elutia Inc. reported third-quarter 2026 net sales of $1.1 million, reflecting a 20% year-over-year increase driven by its cardiovascular business. The company secured $26 million in capital through debt and asset sales without an equity offering, extending its funding runway through the anticipated commercial launch of its lead product, NXT-41x, in 2028. NXT-41x, a drug-eluting matrix designed to prevent surgical infections, successfully met performance endpoints in a GLP rabbit study and is scheduled for FDA submission in the fourth quarter of 2026. Additionally, the company anticipates an FDA clearance decision for the non-drug version, NXT-41, within the same quarter.

Company
ELUTIA INC
Sector
Healthcare
Industry
Medical Devices